Norway’s Navamedic reported Consumer Health segment sales up by almost a fifth in the third quarter as it continued to expand its OTC offering in the Nordics.
Navamedic’s OTC Sales Grow Double Digits As It Takes Eroxon To Finland
Finland is the latest market launch for OTC erectile dysfunction treatment Eroxon. High demand for the product in other countries, such as Norway, helped drive up Navamedic's consumer health sales in the first nine months of 2024.

More from Earnings
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.